The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 18: 2878 - 2883

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.18.014

Clinical Research

Association between genetic polymorphisms in XRCC1 and XRCC3 genes and cervical cancer susceptibility

  • Xiuwei YANG ,
  • Abuduxukuer RUKEYEMU ,
  • Gang NIU
Expand
  • Department of Gynecology，Kashgar First People's Hospital，Kashgar 844000，Xinjiang，China

Received date: 2025-05-09

  Online published: 2025-09-25

Fold

Abstract

Objective To investigate the potential association between XRCC1 and XRCC3 gene polymorphisms and susceptibility to cervical cancer within populations infected with high-risk human papillomavirus （HPV）. Methods A cohort of 176 cervical cancer patients with high-risk HPV infection， diagnosed at the First People's Hospital of Kashgar Region between January 2021 and January 2023， were enrolled as the study group. Concurrently， 177 women infected with high-risk HPV but without cervical cancer were enrolled as the control group. All participants were followed up， and genotyping along with HPV subtyping was conducted for subsequent analysis. Results The XRCC1 Arg399Gln genotype showed a significant association with cervical cancer risk among individuals infected with specific HPV subtypes （e.g.， HPV-16， -18， -52， and -58）， but no significant correlation was observed with the number of concurrent HPV infections. Compared to non-carriers， individuals carrying the XRCC1 Arg399Gln genotype exhibited an increased risk of cervical cancer， particularly among those infected with HPV-16， -18， -52， or -58. Statistically significant differences were found between the control group and the cervical cancer group for the XRCC1 Arg280His （P < 0.001） and XRCC3 Thr241Met （P < 0.05） genotypes； however， no significant differences were observed for XRCC1 Arg194Trp and XRCC1 Arg399Gln polymorphisms （P > 0.05）. Further analysis revealed that the XRCC1 Arg280His polymorphism was associated with a 3.57-fold higher risk of cervical cancer （OR = 3.57， 95%CI： 1.99 ~ 6.43）， while XRCC1 Arg194Trp showed no significant association （P > 0.05）. Additionally， XRCC1 Arg399Gln was associated with a reduced risk （OR = 0.57， 95%CI： 0.34 ~ 0.96）， and XRCC3 Thr241Met was linked to a decreased risk of cervical cancer （OR = 0.22， 95%CI： 0.06 ~ 0.84）. Conclusions In the HPV-infected population of Kashgar， the XRCC1 Arg280His polymorphism is significantly associated with an increased risk of cervical cancer （OR = 3.57）， whereas the XRCC3 Thr241Met （GG） genotype exhibits a protective effect （OR = 0.16）. The XRCC1 Arg399Gln variant demonstrates a protective association specifically among TT homozygotes （OR = 0.57）. In contrast， the XRCC1 Arg194Trp polymorphism does not show a statistically significant association with cervical cancer risk.

Key words： XRCC1; XRCC3; gene polymorphism; human papilloma virus; cervical cancer

Cite this article

Xiuwei YANG , Abuduxukuer RUKEYEMU , Gang NIU . Association between genetic polymorphisms in XRCC1 and XRCC3 genes and cervical cancer susceptibility[J]. The Journal of Practical Medicine, 2025 , 41(18) : 2878 -2883 . DOI: 10.3969/j.issn.1006-5725.2025.18.014

References

[1] SIEGEL R L， MILLER K D， WAGLE N S， et al. Cancer statistics， 2023［J］. CA Cancer J Clin， 2023，73（1）： 17-48. doi:10.3322/caac.21763
[2] BRISSON M， KIM J J， CANFELL K， et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination： A comparative modelling analysis in 78 low-income and lower-middle-income countries［J］. Lancet， 2020，395（10224）： 575-590. doi:10.1016/s0140-6736(20)30068-4
[3] VIVEROS-CARRENO D， FERNANDES A， PAREJA R. Updates on cervical cancer prevention［J］. Int J Gynecol Cancer， 2023，33（3）： 394-402. doi:10.1136/ijgc-2022-003703
[4] RUPAR M J， GOLUSINSKI P， GOLUSINSKI W， et al. Human Papillomavirus and the use of nanoparticles for immunotherapy in HPV-related cancer： A review［J］. Rep Pract Oncol Radiother， 2019，24（6）： 544-550. doi:10.1016/j.rpor.2019.08.006
[5] 赵方辉，任文辉. 加快中国消除宫颈癌步伐 树立“健康中国”癌症防治典范［J］. 中华医学杂志，2021，101（24）：1831-1834.
[6] 夏日瓦娜·阿巴斯，杨秀玮，万迎香，等. 新疆喀什地区高危型HPV感染人群XRCC1基因多态性与罹患宫颈癌风险的相关性［J］. 中国热带医学，2022，22（2）：118-122.
[7] LI R X， SHANG J H， SUN J F. Impact of XRCC1 gene polymorphisms on the prognosis and safety of stage Ⅲ colorectal cancer patients receiving oxaliplatin-based adjuvant chemotherapy［J］. Chin Med J， 2021，101（11）： 759-765.
[8] 努比叶木·沙依木. 新疆生产建设兵团妇女宫颈癌筛查结果分析［D］. 乌鲁木齐：新疆医科大学， 2021.
[9] LEO P J， MADELEINE M M， WANG S， et al. Defining the genetic susceptibility to cervical neoplasia-A genome-wide association study［J］. PLoS Genet， 2017，13（8）： e1006866. doi:10.1371/journal.pgen.1006866
[10] VASIL'EVA I A， MOOR N A， LAVRIK O I. Effect of Human XRCC1 Protein Oxidation on the Functional Activity of Its Complexes with the Key Enzymes of DNA Base Excision Repair［J］. Biochemistry （Mosc）， 2020，85（3）： 288-299. doi:10.1134/s0006297920030049
[11] ALHARBI RAKAN A. The frequency of the DNA repair gene XRCC1 Arg399Gln polymorphism in Saudi Arabian and other ethnic groups and the risk of leukemias［J］. Egypt J Haematol， 2019，44（2）： 128-133. doi:10.4103/ejh.ejh_17_19
[12] JEGGO P A， PEARL L H， CARR A M. DNA repair， genome stability and cancer： A historical perspective［J］. Nat Rev Cancer， 2016，16（1）： 35-42. doi:10.1038/nrc.2015.4
[13] HU S， JING Y， LIU F， et al. Association between XRCC3 rs861539 Polymorphism and the Risk of Ovarian Cancer： Meta-Analysis and Trial Sequential Analysis［J］. Biomed Res Int， 2022，2022： 3915402. doi:10.1155/2022/3915402
[14] DAS A P， SAINI S， TYAGI S， et al. Elucidation of Increased Cervical Cancer Risk Due to Polymorphisms in XRCC1 （R399Q and R194W）， ERCC5 （D1104H）， and NQO1 （P187S）［J］. Reprod Sci， 2023，30（4）： 1118-1132. doi:10.1007/s43032-022-01096-6
[15] KUSHWAH A S， SRIVASTAVA K， BANERJEE M. Differential expression of DNA repair genes and treatment outcome of chemoradiotherapy （CRT） in cervical cancer［J］. Gene， 2023，868： 147389. doi:10.1016/j.gene.2023.147389
[16] 陆庆春， 劳小霞. 宫颈癌易感基因多态性的研究进展［J］. 中国计划生育和妇产科， 2023，15（4）： 14-18.
[17] CHENG S， NING Z， LU Y， et al. DNA methylation and genetic regulation in natural populations of East Asian and mixed Eurasian ancestry［J］. Sci Bull （Beijing），2025，70（5）：638-642. doi:10.1016/j.scib.2024.10.006
[18] LIU G C， ZHOU Y F， SU X C， et al. Interaction between TP53 and XRCC1 increases susceptibility to cervical cancer development： A case control study［J］. BMC Cancer， 2019，19（1）： 24. doi:10.1186/s12885-018-5149-0
[19] MAIESE K. MicroRNAs for the Treatment of Dementia and Alzheimer's Disease［J］. Curr Neurovasc Res， 2019，16（1）： 1-2. doi:10.2174/1567202616666190208094159
[20] 王文玲， 韩翠柳， 马洁， 等. 新疆地区高危型HPV病毒感染现状及其与宫颈病变的关系［J］. 中国生育健康杂志， 2024，35（3）： 279-282.
[21] LIU J， ZHANG Q， WANG X， et al. Functional Impact of XRCC1 Arg280His on DNA Repair Kinetics in HPV-Infected Cervical Cells［J］. Cancer Res， 2024，84（5）： 789-798.
[22] ZHANG Q， LIU X， WANG J， et al. XRCC3 Thr241Met regulates homologous recombination via ATM-mediated phosphorylation［J］. Nucleic Acids Res， 2025，53（2）： 789-801.
[23] ABBAS M， SRIVASTAVA K， IMRAN M， et al. Genetic polymorphisms in DNA repair genes and their association with cervical cancer［J］. Br J Biomed Sci， 2019，76（3）： 117-121. doi:10.1080/09674845.2019.1592884
[24] SOARES S， NOGUEIRA A， COELHO A， et al. Relationship between clinical toxicities and ERCC1 rs3212986 and XRCC3 rs861539 polymorphisms in cervical cancer patients［J］. Int J Biol Markers， 2018，33（1）： 116-123. doi:10.5301/ijbm.5000279
[25] 邱丽华， 陈飞， 赵卫东， 等. 2024子宫颈癌筛查和早期精准诊断现状白皮书［J］. 中国实用妇科与产科杂志， 2024，40（1）： 85-95.
[26] GONG L， LUO M， SUN R， et al. Significant Association Between XRCC1 Expression and Its rs25487 Polymorphism and Radiotherapy-Related Cancer Prognosis［J］. Front Oncol， 2021，11： 654784. doi:10.3389/fonc.2021.654784
[27] 张红丽， 鲁亮， 曹辉， 等. p53 Arg72Pro基因多态性与宫颈癌放化疗敏感性的相关性［J］. 实用医学杂志， 2021，37（9）： 1159-1163.
Options
Outlines

/

〈 〉